Live-attenuated lymphocytic choriomeningitis virus-based vaccines for active immunotherapy of HPV16-positive cancer

References

• Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100(6):407–12. doi:10.1093/jnci/djn025.
   PubMed Web of Science ®Google Scholar
• Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, Lyu CW, Steinau M, Watson M, Wilkinson EJ, Hopenhayn C. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015;107(6):djv086. doi:10.1093/jnci/djv086.
   PubMedGoogle Scholar
• Frazer IH, Chandra J. Immunotherapy for HPV associated cancer. Papillomavirus Res. 2019;8:100176. doi:10.1016/j.pvr.2019.100176.
   PubMed Web of Science ®Google Scholar
• Balermpas P, Rodel F, Rodel C, Krause M, Linge A, Lohaus F, Baumann M, Tinhofer I, Budach V, Gkika E, et al. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). Int J Cancer. 2016;138(1):171–181. doi:10.1002/ijc.29683.
   PubMed Web of Science ®Google Scholar
• Barnes TA, Amir E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br J Cancer. 2017;117(4):451–460. doi:10.1038/bjc.2017.220.
   PubMed Web of Science ®Google Scholar
• Ward MJ, Thirdborough SM, Mellows T, Riley C, Harris S, Suchak K, Webb A, Hampton C, Patel NN, Randall CJ, et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer. 2014;110(2):489–500. doi:10.1038/bjc.2013.639.
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956–965. doi:10.1016/S1470-2045(16)30066-3.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wu L, Tong R, Yang F, Yin L, Li M, You L, Xue J, Lu Y. PD-1/PD-L1 Inhibitors in Cervical Cancer. Front Pharmacol. 2019;10:65. doi:10.3389/fphar.2019.00065.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G Jr., Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 1856-67;2016:375.
   Google Scholar
• Shibata T, Lieblong BJ, Sasagawa T, Nakagawa M. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. Cancer Treat Rev. 2019;78:8–16. doi:10.1016/j.ctrv.2019.07.001.
   PubMed Web of Science ®Google Scholar
• Araldi RP, Assaf SMR, Carvalho RF, et al. Papillomaviruses: a systematic review. Genet Mol Biol. 2017;40:1–21.
   PubMed Web of Science ®Google Scholar
• Dadar M, Chakraborty S, Dhama K, et al. Advances in designing and developing vaccines, drugs and therapeutic approaches to counter human papilloma virus. Front Immunol. 2018;9:2478.
   PubMed Web of Science ®Google Scholar
• Conesa-Zamora P. Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape. Gynecol Oncol. 2013;131(2):480–488. doi:10.1016/j.ygyno.2013.08.025.
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR, Lowik MJG, Berends-van der Meer DMA, Vloon APG, Essahsah F, Fathers LM, Offringa R, Drijfhout JW. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838–1847. doi:10.1056/NEJMoa0810097.
   PubMed Web of Science ®Google Scholar
• Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386(10008):2078–2088. doi:10.1016/S0140-6736(15)00239-1.
   PubMed Web of Science ®Google Scholar
• Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu T-E, Bosquée L, Trigo JM, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(1):59–68. doi:10.1016/S1470-2045(13)70510-2.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422. doi:10.1056/NEJMoa1001294.
   PubMed Web of Science ®Google Scholar
• Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(6):822–835. doi:10.1016/S1470-2045(16)00099-1.
   PubMed Web of Science ®Google Scholar
• Kallert SM, Darbre S, Bonilla WV, et al. Replicating viral vector platform exploits alarmin signals for potent CD8(+) T cell-mediated tumour immunotherapy. Nat Commun. 2017;8:15327. doi:10.1038/ncomms15327.
   PubMed Web of Science ®Google Scholar
• Kotturi MF, Swann JA, Peters B, Arlehamn CL, Sidney J, Kolla RV, James EA, Akondy RS, Ahmed R, Kwok WW, et al. Human CD8(+) and CD4(+) T cell memory to lymphocytic choriomeningitis virus infection. J Virol. 2011;85(22):11770–11780. doi:10.1128/JVI.05477-11.
   PubMed Web of Science ®Google Scholar
• de Lamballerie X, Fulhorst CF, Charrel RN. Prevalence of antibodies to lymphocytic choriomeningitis virus in blood donors in southeastern France. Transfusion. 2007;47(1):172–173. doi:10.1111/j.1537-2995.2007.01081.x.
   PubMed Web of Science ®Google Scholar
• Stephensen CB, Blount SR, Lanford RE, Holmes KV, Montali RJ, Fleenor ME, Shaw JFE. Prevalence of serum antibodies against lymphocytic choriomeningitis virus in selected populations from two U.S. Cities. J Med Virol. 1992;38(1):27–31. doi:10.1002/jmv.1890380107.
   PubMed Web of Science ®Google Scholar
• Sommerstein R, Flatz L, Remy MM, Malinge P, Magistrelli G, Fischer N, Sahin M, Bergthaler A, Igonet S, Ter Meulen J. Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection. PLoS Pathog. 2015;11(11):e1005276. doi:10.1371/journal.ppat.1005276.
   PubMed Web of Science ®Google Scholar
• Atherton MJ, Stephenson KB, Pol J, Wang F, Lefebvre C, Stojdl DF, Nikota JK, Dvorkin-Gheva A, Nguyen A, Chen L, et al. Customized viral immunotherapy for HPV-associated cancer. Cancer Immunol Res. 2017;5(10):847–859. doi:10.1158/2326-6066.CIR-17-0102.
   PubMed Web of Science ®Google Scholar
• Cassetti MC, McElhiney SP, Shahabi V, Pullen JK, Le Poole IC, Eiben GL, Smith LR, Kast WM. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine. 2004;22(3–4):520–527. doi:10.1016/j.vaccine.2003.07.003.
   PubMed Web of Science ®Google Scholar
• Flatz L, Hegazy AN, Bergthaler A, Verschoor A, Claus C, Fernandez M, Gattinoni L, Johnson S, Kreppel F, Kochanek S. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med. 2010;16(3):339–345. doi:10.1038/nm.2104.
   PubMed Web of Science ®Google Scholar
• Venkatesan A, Murphy OC. Viral encephalitis. Neurol Clin. 2018;36(4):705–724. doi:10.1016/j.ncl.2018.07.001.
   PubMed Web of Science ®Google Scholar
• Lin KY, Guarnieri FG, Staveley-O’Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56:21–26.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhou H, Wang W, Fu YX, Zhu M. A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice. Oncoimmunology. 2016;5(6):e1147641. doi:10.1080/2162402X.2016.1147641.
   PubMed Web of Science ®Google Scholar
• Grunwitz C, Salomon N, Vascotto F, Selmi A, Bukur T, Diken M, Kreiter S, Türeci Ö, Sahin U. HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory. Oncoimmunology. 2019;8(9):e1629259. doi:10.1080/2162402X.2019.1629259.
   PubMed Web of Science ®Google Scholar
• Knipe DM, Howley PM. Chapter 43. Arenavirus. Fields virology. Vol. 1333. 6th ed. Philadelphia (PA): Wolters Kluwer/Lippincott Williams & Wilkins Health; 2013.
   Google Scholar
• Brun JL, Dalstein V, Leveque J, et al. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol. 2011;204:169:e1–8.
   Web of Science ®Google Scholar
• Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP, Magill M, Silverman M, Urban RG, Hedley ML. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2004;103(2):317–326. doi:10.1097/01.AOG.0000110246.93627.17.
   PubMed Web of Science ®Google Scholar
• Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, Wu TC. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res. 2001;61:3698–3703.
   PubMed Web of Science ®Google Scholar
• Melief CJ. Treatment of established lesions caused by high-risk human papilloma virus using a synthetic vaccine. J Immunother. 2012;35(3):215–216. doi:10.1097/CJI.0b013e318248f17f.
   PubMed Web of Science ®Google Scholar
• Wu A, Zeng Q, Kang TH, Peng S, Roosinovich E, Pai SI, Hung C-F. Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer. Gene Ther. 2011;18(3):304–312. doi:10.1038/gt.2010.151.
   PubMed Web of Science ®Google Scholar
• Aebischer O, Meylan P, Kunz S, Lazor-Blanchet C. Lymphocytic choriomeningitis virus infection induced by percutaneous exposure. Occup Med (Lond). 2016;66(2):171–173. doi:10.1093/occmed/kqv156.
   PubMed Web of Science ®Google Scholar
• Webb HE, Molomut N, Padnos M, Wetherley-Mein G. The treatment of 18 cases of malignant disease with an arenavirus. Clin Oncol. 1975;1:157–169.
   PubMedGoogle Scholar
• Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, Helmus N, Vogels R, Bakker M, Berkhout B, Havenga M. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS. 2004;18(8):1213–1216. doi:10.1097/00002030-200405210-00019.
   PubMed Web of Science ®Google Scholar
• Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature. 2006;441(7090):239–243. doi:10.1038/nature04721.
   PubMed Web of Science ®Google Scholar
• Pinschewer DD, Perez M, Jeetendra E, Bächi T, Horvath E, Hengartner H, Whitt MA, de la Torre JC, Zinkernagel RM. Kinetics of protective antibodies are determined by the viral surface antigen. J Clin Invest. 2004;114(7):988–993. doi:10.1172/JCI200422374.
   PubMed Web of Science ®Google Scholar
• Kalkavan H, Sharma P, Kasper S, Helfrich I, Pandyra AA, Gassa A, Virchow I, Flatz L, Brandenburg T, Namineni S. Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. Nat Commun. 2017;8(1):14447. doi:10.1038/ncomms14447.
   PubMedGoogle Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• Ghanizada M, Jakobsen KK, Gronhoj C, von Buchwald C. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review. Oral Oncol. 2019;90:67–73. doi:10.1016/j.oraloncology.2019.01.018.
   PubMed Web of Science ®Google Scholar
• Lin PL, Cheng YM, Wu DW, Huang Y-J, Lin H-C, Chen C-Y, Lee H. A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers. Cancer Med. 2017;6(9):2052–2062. doi:10.1002/cam4.1143.
   PubMed Web of Science ®Google Scholar
• Massarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M, Feng L, Lee JJ, Tran H, Kim YU. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial. JAMA Oncol. 2019;5(1):67–73. doi:10.1001/jamaoncol.2018.4051.
   PubMed Web of Science ®Google Scholar
• Moeini S, Saeidi M, Fotouhi F, Mondanizadeh M, Shirian S, Mohebi A, Gorji A, Ghaemi A. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine. Arch Virol. 2017;162(2):333–346. doi:10.1007/s00705-016-3091-5.
   PubMed Web of Science ®Google Scholar
• Rice AE, Latchman YE, Balint JP, Lee JH, Gabitzsch ES, Jones FR. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. Cancer Gene Ther. 2015;22(9):454–462. doi:10.1038/cgt.2015.40.
   PubMed Web of Science ®Google Scholar
• Eissa IR, Bustos-Villalobos I, Ichinose T, et al. The current status and future prospects of oncolytic viruses in clinical trials against melanoma, glioma, pancreatic, and breast cancers. Cancers (Basel). 2018;10(10):356. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210336/.
   PubMed Web of Science ®Google Scholar
• Ring S, Flatz L. Generation of lymphocytic choriomeningitis virus based vaccine vectors. Methods Mol Biol. 2016;1404:351–364.
   PubMedGoogle Scholar
• Cardin RD, Bravo FJ, Pullum DA, Orlinger K, Watson EM, Aspoeck A, Fuhrmann G, Guirakhoo F, Monath T, Bernstein DI. Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection. Vaccine. 2016;34(17):1993–1999. doi:10.1016/j.vaccine.2016.03.005.
   PubMed Web of Science ®Google Scholar
• Bonilla WV, Frohlich A, Senn K, Kallert S, Fernandez M, Johnson S, Kreutzfeldt M, Hegazy AN, Schrick C, Fallon PG, et al. The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses. Science. 2012;335(6071):984–989. doi:10.1126/science.1215418.
   PubMed Web of Science ®Google Scholar